Streetbeat News

Regulatory

COSM

Cosmos Health Inc. has regained compliance with Nasdaq's Listing Rule 5250(c)(1) after filing its 2023 Annual Report and first quarter 2024 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 1:37 pm

RDY

Dr. Reddy's Laboratories received an FDA Form 483 with three observations after an inspection at its Srikakulam facility. This could indicate potential compliance issues that may need to be addressed.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 1:31 pm

SPY

Federal Reserve's Bostic estimates the long-run policy rate at 3% and states that future rate decisions will depend on upcoming data, with possibilities ranging from no rate cut to a 50 basis point cut.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 1:20 pm

JAZZ

Jazz Pharmaceuticals reported results from a Phase 3 trial in Japan for Epidiolex, a CBD treatment for severe epilepsy. The trial did not meet its primary goal but showed numeric improvements and no new safety issues. Jazz plans to engage with Japanese regulatory authorities for a potential new drug application.

Portfolio Pulse from Nina Zdinjak

August 23, 2024 | 1:15 pm

APDN

Applied DNA Sciences has submitted a validation package to the New York State Department of Health to expand the use of its Linea Mpox Virus 1.0 Assay to detect additional mpox clades. The assay has shown 100% homology to mpox clade I and clade Ib, which is significant given the WHO's recent public health emergency declaration. Approval from NYSDOH is pending.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 1:02 pm

SPY

Federal Reserve's Raphael Bostic emphasized the need for patience in determining the future policy pathway. This suggests a cautious approach to interest rate changes, which could impact market sentiment and investor decisions.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 12:48 pm

SPY

Atlanta Federal Reserve President Raphael Bostic stated that recent job revision figures did not significantly alter his economic outlook. This suggests stability in his perspective on monetary policy and economic conditions.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 12:46 pm

SPY

Federal Reserve's Raphael Bostic expressed increased confidence in inflation returning to the 2% target, based on recent data. However, he cautioned that the journey is not over and emphasized the importance of upcoming data points.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 12:44 pm

SPY

Fed's Bostic suggests that the Federal Reserve is nearing readiness to cut interest rates, emphasizing the need for a calm return to normal policy. The labor market is seen as a sign of normalization, and policy changes may occur before inflation hits 2%.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 12:41 pm

AZN

AstraZeneca is considering relocating its vaccine production from the UK to Philadelphia due to reduced state support from the UK government. The company is exploring alternative sites with better financial incentives, as the UK government plans to cut financial aid significantly. This move could impact the UK's status in the life sciences sector.

Portfolio Pulse from Vandana Singh

August 23, 2024 | 12:39 pm